Conditions: Stage I Breast Cancer Stage II Breast Cancer Stage III Breast Cancer Invasive Breast Cancer
Keywords: Preoperative Neoadjuvant
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 2
Healthy volunteers: no

Brief summary:
This research study is designed to look at the effects of the combination of vorinostat (Suberoylanilide Hydroxamic Acid or Zolinza) and tamoxifen on breast cancer tissue. The investigators will do this by comparing tissues from the original breast biopsy to tissues obtained after taking vorinostat and tamoxifen for 2 weeks.

Detailed description:
Key eligibility criteria include:

* Newly diagnosed invasive breast cancer awaiting surgery or neoadjuvant (preoperative) treatment
* No use of hormone contraceptives or replacement therapy within 30 days prior to the diagnostic breast cancer biopsy (unless willing to have an additional biopsy prior to starting the study)
* No prior or current use of any therapy to treat the current breast cancer.

Arms:
arm 1: Vorinostat and tamoxifen are taken for about 14 days prior to definitive surgery.

Interventions: intervention 1: Vorinostat and Tamoxifen
Intervention descriptions: intervention 1: vorinostat 400 mg PO once daily and tamoxifen 20mg PO once daily for 14 days

Protocol document: